openPR Logo
Press release

Investigation for Investors in NASDAQ: MYL shares over potential Securities Laws Violations by Mylan N.V.

11-14-2019 11:11 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Mylan N.V. (NASDAQ: MYL) shares over potential securities laws violations by Mylan N.V.

An investigation for investors in Mylan N.V. (NASDAQ: MYL) shares over potential securities laws violations by Mylan N.V.

Mylan N.V. is under investigation concerning potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Mylan N.V. (NASDAQ: MYL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Mylan N.V. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

United Kingdom based Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. Mylan N.V. reported that its annual Total Revenue declined from over $11.9 billion in 2017 to over $11.43 billion in 2018 and that its Net Income declined from $696 Million in 2017 to $352.5 million in 2018.

Shares of Mylan N.V. (NASDAQ: MYL) declined from $47.19 per share in early 2018 to as low as $16.63 per share in May 2019.

On November 14, 2019, NASDAQ: MYL shares closed at $17.26 per share.

Those who purchased shares of Mylan N.V. (NASDAQ: MYL) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Investors in NASDAQ: MYL shares over potential Securities Laws Violations by Mylan N.V. here

News-ID: 1867667 • Views: 595

More Releases from Shareholders Foundation

Lawsuit filed for Investors in Energy Transfer LP (NYSE: ET) over alleged Mislea …
An investor in Energy Transfer LP (NYSE: ET) filed a lawsuit over alleged violations of Federal Securities Laws by Energy Transfer LP in connection with certain allegedly false and misleading statements. Investors who purchased units of Energy Transfer LP (NYSE: ET) have certain options and for certain investors are short and strict deadlines running. Deadline: January 20, 2020. NYSE: ET investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Investors in shares of CBL & Associates Properties, …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at CBL & Associates Properties, Inc. Investors who purchased shares of CBL & Associates Properties, Inc (NYSE: CBL) and currently hold any of those NYSE: CBL shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain CBL & Associates Properties
Lawsuit filed for Investors in shares of Aurora Cannabis Inc. (NYSE: ACB)
The Shareholders Foundation announced that an investor, who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), filed a lawsuit over alleged violations of Federal Securities Laws by Aurora Cannabis Inc. Investors who purchased shares of Aurora Cannabis Inc. (NYSE: ACB), have certain options and for certain investors are short and strict deadlines running. Deadline: January 21, 2020. NYSE: ACB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Verb Technology Com …
An investigation on behalf of current long-term investors in shares of Verb Technology Company, Inc. (NASDAQ: VERB) concerning potential breaches of fiduciary duties by certain directors and officers of Verb Technology Company, Inc. was announced. Investors who are current long term investors in Verb Technology Company, Inc. (NASDAQ: VERB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a

All 5 Releases


More Releases for Mylan

Global Trazodone Hydrochloride (API) Market 2018 - Teva, Angelini, Mylan, Fermio …
Apex Market Reports, recently published a detailed market research study focused on the “Trazodone Hydrochloride (API) Market” across the global, regional and country level. The report provides 360° analysis of “Trazodone Hydrochloride (API) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Trazodone
Global Capecitabine Market 2018 - Roche, Teva, Mylan, Hikma, Cipla
Apex Market Reports, recently published a detailed market research study focused on the “Capecitabine Market” across the global, regional and country level. The report provides 360° analysis of “Capecitabine Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Capecitabine on the basis of
Global Perphenazines Market 2018 - Teva, Sandoz, Endo, Mylan
Apex Market Reports, recently published a detailed market research study focused on the “Perphenazines Market” across the global, regional and country level. The report provides 360° analysis of “Perphenazines Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Perphenazines on the basis of
Narcolepsy Drug Market Size 2017-2022 Novartis, Mylan, Teva Pharmaceutical
In the last several years, global market of narcolepsy drug developed rapidly, with an average growth rate of 9.6%. In 2016, global revenue of narcolepsy drug is nearly 1725 M USD; the actual production is about 48380 Kg. The global average price of narcolepsy drug is in the decreasing trend, from 43.3 K USD/Kg in 2012 to 35.7 K USD/Kg in 2016. With the situation of global economy, prices will
Sulindacs Market Size 2017-2022 Merck, MYLAN, EPIC, HERITAGE, TEAM
Global Sulindacs Market Research Report Recently published a detailed market study on the "Sulindacs Market" across the global, regional and country level. The report on the global Sulindacs market uses the top-down and bottom-up approaches to define, analyze, and describe the market trends for the next five years. The Sulindacs market report further provides production, capacity, Sulindacs market price per region, gross margin, production cost, for all major regions and countries
Desipramine Market Size 2017-2022 Pfizer, Teva, Emcure, Novartis, Mylan
Global Desipramine Market Research Report Recently published a detailed market study on the "Desipramine Market" across the global, regional and country level. The report on the global Desipramine market uses the top-down and bottom-up approaches to define, analyze, and describe the market trends for the next five years. The Desipramine market report further provides production, capacity, Desipramine market price per region, gross margin, production cost, for all major regions and countries